Nuwellis Overhauls Board, Ties New Directors to $5M Capital Raise

MINNEAPOLIS, MN – January 23, 2026 – Nuwellis, Inc. (Nasdaq: NUWE), the medical technology firm focused on cardiorenal care, announced a significant overhaul of its Board of Directors this week, appointing two new members while accepting the resignations of three others. While the company characterized the departures as amicable, deeper analysis reveals the leadership shuffle is directly tied to the company's urgent need to secure fresh capital, making this a pivotal moment for the micro-cap firm.

In a press release, Nuwellis announced the appointments of Katharyn Field and Mika Grasso and the simultaneous resignations of Dave McDonald, Mike McCormick, and Dr. Maria Costanzo, all effective January 21, 2026. The company also reduced its board size from six members to five.

“We are pleased to welcome Katharyn and Mika to the Board and look forward to benefiting from their financial, operational, and governance experience as we continue executing our strategic priorities,” said John L. Erb, President and Chief Executive Officer of Nuwellis, in the official statement.

However, a Form 8-K filed with the Securities and Exchange Commission on January 21 provides critical context not present in the public announcement. The appointments of both Ms. Field and Mr. Grasso are contingent upon a future financing event. Both new directors have agreed to resign if Nuwellis fails to secure an equity investment of at least $5 million within a specified period, directly linking this board refreshment to the company's financial stability and near-term fundraising efforts.

A Strategic Pivot Tied to Capital

The conditional nature of the new appointments shines a spotlight on Nuwellis's current financial position. The company, which has a market capitalization of approximately $3.55 million, has been navigating a challenging financial landscape. While its third-quarter 2025 results showed a surprising net income of $469,000, this was set against a 6% year-over-year decline in revenue. Financial reports indicate the company is burning through its cash reserves, making a capital infusion not just strategic, but essential for its operations and growth.

The decision to bring on directors whose tenures are explicitly linked to a successful capital raise sends a clear signal to the market: Nuwellis is prioritizing financial fortification. This move is designed to build investor confidence by demonstrating that the new leadership is directly invested in and accountable for the company’s financial success. It transforms a routine governance change into a public benchmark for the company’s ability to execute its financial strategy.

New Expertise for New Challenges

The backgrounds of the incoming directors, Katharyn Field and Mika Grasso, are precisely aligned with the company's apparent needs for operational execution and financial acumen.

Katharyn Field brings a wealth of executive leadership and corporate governance experience. As the current CEO of iSpecimen Inc., she is tasked with performance improvement and software redevelopment. Her extensive resume includes CEO and Chairman roles at Halo Collective and board positions at multiple other public companies, including Virpax Pharmaceuticals and Akanda Corporation. With an MBA in Strategy and Economics from Columbia Business School, her expertise in corporate strategy, development, and operational oversight is poised to help Nuwellis navigate its next phase of growth and commercialization.

Mika Grasso provides a deep well of knowledge in finance and investment markets, a critical asset for a company actively seeking capital. Currently an Investment Manager at a private family office, his career includes roles as an Investment Banking Associate at Paulson Investment Company and an Analyst at Goldman Sachs. His direct experience in evaluating investment opportunities and navigating capital markets from the inside is invaluable for a micro-cap company like Nuwellis looking to attract sophisticated investors. His appointment suggests a concerted effort to strengthen the board's financial oversight and capital-raising capabilities.

Together, their appointments signal a strategic shift towards a board with a heavy emphasis on financial strategy, operational discipline, and governance—key attributes needed to steer a small medical technology company through a competitive and capital-intensive industry.

Analyzing the Departures

While the addition of Field and Grasso brings new strengths, the departure of Dave McDonald, Mike McCormick, and Dr. Maria Costanzo creates a significant experience vacuum. The company confirmed the resignations were not the result of any disagreement, but the simultaneous exit of three seasoned directors is noteworthy.

Dave McDonald brought extensive life science investment banking and business development experience. Mike McCormick is a veteran medical device executive who previously served as CEO of Osprey Medical and successfully sold another company, Anulex Technologies, to Boston Scientific. Dr. Maria Costanzo, a medical director specializing in heart failure research, provided direct clinical expertise highly relevant to Nuwellis's cardiorenal focus.

Their collective departure removes decades of specific medtech operational, financial, and clinical knowledge from the boardroom. While the board is now leaner, the loss of this institutional and industry-specific wisdom represents a calculated trade-off. The company is betting that the focused financial and strategic execution skills of its new members will outweigh the loss of the outgoing directors' broader experience as it tackles its immediate priority: securing funding.

Navigating a Competitive MedTech Landscape

Nuwellis's board restructuring reflects broader trends within the medical technology sector. The investment climate has grown more disciplined, with investors demanding clear paths to profitability and strong corporate governance. For smaller companies, securing funding is a constant battle, and demonstrating a sound strategy led by a capable board is paramount.

The company is not standing still on the innovation front. It recently announced a new U.S. patent for its blood filtration systems, aimed at pediatric patients, and has seen positive clinical data presented on its flagship Aquadex SmartFlow® system. These developments are crucial for building value and creating a compelling story for potential investors.

Ultimately, the overhaul of the Nuwellis board is a clear and decisive action. By bringing in new leaders with strong financial and operational pedigrees and publicly tying their tenure to a successful $5 million capital raise, the company has placed a high-stakes wager on its new direction. The success of this strategic pivot will now be measured not just in future earnings reports, but by its ability to close the funding round that underpins its very leadership structure.